Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cutaneous Lymphangiosis Carcinomatosa in Lung Cancer.

Deutsches Arzteblatt international·2026
Same author

Response to Barnawi et al., "Bullous pemphigoid in the era of immunotherapy: Implications for treatment algorithms".

Journal of the American Academy of Dermatology·2026
Same author

Bidirectional association between immunobullous diseases and obsessive-compulsive disorder including excoriation disorder.

Archives of dermatological research·2026
Same author

Diagnosis of immunobullous diseases in underrepresented groups: an all of us database study.

Archives of dermatological research·2026
Same author

International development of Investigator Global Assessment scores for pemphigus.

Journal of the European Academy of Dermatology and Venereology : JEADV·2026
Same author

Complement Activation May Drive the Pathogenicity of Anti-α6 and Anti-β4 Integrin Antibodies In Vivo.

Biomolecules·2026
Same journal

Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials.

The British journal of dermatology·2026
Same journal

Clinicopathological features of lymphocytic thrombophilic arteritis and the relationship with livedoid vasculopathy - a case series of 36 patients.

The British journal of dermatology·2026
Same journal

Improving Prognostication for Cutaneous Squamous Cell Carcinoma.

The British journal of dermatology·2026
Same journal

Recurrent and novel GLTP variants in five patients with nonsyndromic epidermal differentiation disorder: phenotypic and genotypic expansion.

The British journal of dermatology·2026
Same journal

Sustained efficacy of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis over 1 year.

The British journal of dermatology·2026
Same journal

EPHX3-nEDD: from molecular diagnosis to epidermal lipid biology.

The British journal of dermatology·2026
See all related articles

Related Experiment Video

Updated: May 5, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K

Anti-p200 pemphigoid.

Michael Kasperkiewicz1, Manuela Pigors2, Maike M Holtsche2,3

  • 1Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA.

The British Journal of Dermatology
|August 25, 2025
PubMed
Summary
This summary is machine-generated.

Anti-p200 pemphigoid is an autoimmune blistering disease. Current evidence suggests laminin β4 is the primary target antigen, aiding diagnosis and understanding of this condition.

More Related Videos

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

276

Related Experiment Videos

Last Updated: May 5, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
10:27

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

24.6K
Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

10.6K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

276

Area of Science:

  • Dermatology
  • Immunology
  • Autoimmune Bullous Diseases

Background:

  • Anti-p200 pemphigoid is an autoimmune bullous disorder presenting with blisters and erosions.
  • It shares clinical features with bullous pemphigoid and epidermolysis bullosa acquisita.
  • Autoantibodies target a 200 kDa protein at the dermal-epidermal junction.

Purpose of the Study:

  • To summarize current knowledge on anti-p200 pemphigoid.
  • To review epidemiology, clinical presentation, diagnosis, and pathophysiology.
  • To discuss treatment strategies for this autoimmune condition.

Main Methods:

  • Review of existing literature on anti-p200 pemphigoid.
  • Analysis of diagnostic methods, including indirect immunofluorescence microscopy.
  • Evaluation of target antigens: laminin γ1 and laminin β4.

Main Results:

  • Laminin β4 is identified as the most recent and likely pathophysiologically relevant autoantigen.
  • A standardized assay for anti-laminin β4 IgG facilitates diagnosis.
  • In vitro and ex vivo data support laminin β4's role, but in vivo data are pending.

Conclusions:

  • Anti-p200 pemphigoid diagnosis is enhanced by the availability of anti-laminin β4 IgG detection.
  • Laminin β4 is considered the key autoantigen, though further in vivo studies are needed.
  • Comprehensive understanding of this disease aids in patient management.